ADCs
ADCs
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
Samsung Biologics and LegoChem unite to revolutionize cancer treatment
BIOT
🔍 Samsung Biologics teams up with LegoChem to advance ADCs, combining antibodies and drugs to target cancer cells. 🔬 Collaboration leverages manufacturing expertise and ADC development technology for better cancer treatment options.
